All News
Filter News
Found 808,990 articles
-
NantKwest and ImmunityBio Sign Collaboration Agreement for Joint Development, Manufacturing, Marketing, and Commercialization of COVID-19 Vaccine and Related Therapeutics
8/24/2020
NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately held immunotherapy company, today announced the signing of a definitive agreement to jointly develop, manufacture, market, and commercialize therapeutics and vaccines for combating the COVID-19 pandemic.
-
Forbes Names PPD One of North Carolina’s Best Employers
8/24/2020
PPD, Inc., a leading global contract research organization, has been named to Forbes magazine’s 2020 list of America’s Best-in-State Employers for North Carolina.
-
Chiesi USA, Inc. Earns 2020 Life Sciences Award by Triangle Business JournalChiesi recognized for its continued service to patients, healthcare providers, employees and community partners
8/24/2020
Chiesi USA, a specialty pharmaceutical company based in Cary, North Carolina, was named Company of the Year by the Triangle Business Journal 2020 Life Sciences Awards in honor of its noteworthy work in the life sciences industry.
-
Immunovant Appoints Michael Elliott Chief Scientific OfficerDr. Elliott previously served as Vice President of Immunology Scientific Innovation at J&J and has led the clinical development of multiple blockbuster immunology products
8/24/2020
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced the appointment of Michael Elliott, MBBS, PhD as Chief Scientific Officer.
-
Protalix BioTherapeutics Announces Completion of the Treatment Period for its Phase III BRIGHT Clinical Trial of Pegunigalsidase Alfa (PRX-102) for the Proposed Treatment of Fabry Disease
8/24/2020
Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, announced completion of the treatment period of its Phase III BRIGHT clinical trial of pegunigalsidase alfa, or PRX–102, for the proposed treatment of Fabry disease.
-
Accelerate Diagnostics Names Nedal Safwat Chief Strategy Officer
8/24/2020
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced that Nedal Safwat has been appointed Chief Strategy Officer
-
MITRE and Nuance Use AI to Help Oncologists Quickly and Accurately Collect Data to Improve Cancer Research and Treatment
8/24/2020
Nuance Dragon Medical One cloud-based speech recognition solution reduces burden to clinicians and helps improve quality of available cancer data
-
ImmunoGenesis Awarded $15.5 M Grant from Cancer Prevention and Research Institute of Texas (CPRIT)
8/24/2020
ImmunoGenesis, Inc. today announced that it has been awarded a $15.5 M grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to advance development of IMGS-001, the company’s dual specific Checkpoint Inhibitor and Tumor Microenvironment (TME) remodeling agent. IMGS-001, through its mechanism of action, has the potential to provide superior blockade of the PD-1 pathway and clear out immunosuppressive elements in the TME.
-
Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan
8/24/2020
KEYTRUDA Now Approved for Patients With PD-L1-Positive Esophageal Squamous Cell Carcinoma Who Have Progressed After Chemotherapy and for a Six-Week Dosing Schedule Across All Adult Indications
-
CMPA hosts expert panel -- Lessons in virtual care from the COVID-19 pandemic
8/24/2020
The Canadian Medical Protective Association hosted its first "virtual" Education Session titled Virtual Care in Canada: Lessons from the COVID-19 Pandemic
-
MC2 Therapeutics Announces Collaboration Agreement with EPI Health on Commercialization of Newly Approved Psoriasis Drug, WYNZORA® Cream, in the US
8/24/2020
MC2 Therapeutics, a commercial stage pharmaceutical company focused on innovative topical therapies for chronic inflammatory conditions, announced today its Collaboration Agreement with EPI Health, LLC on the commercialization of WYNZORA Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) in the US.
-
Leap Therapeutics Expands Leadership Team with Addition of Two Industry Veterans
8/24/2020
Jason Baum, Ph.D., Joins as Vice President, Head of Translational Medicine Christine Granfield Named Vice President, Head of Regulatory Affairs and Quality
-
Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Quebec’s RAMQ List of Medications (Basic Plan and Institutions)
8/24/2020
Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF) is pleased to announce that Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (TH) has been approved for inclusion as a general benefit (open listing) on the List of Medications - Basic Plan and the List of Medications - Institutions administered by the Régie de l’assurance maladie du Québec (RAMQ), effective August 19, 2020.
-
Quest Diagnostics and Quest Diagnostics Foundation Launch Initiative to Reduce Health Disparities in Underserved Communities
8/24/2020
Quest to dedicate more than $100 million to expand access to testing, partner to help those hit hardest by COVID-19 and fund Foundation initiatives
-
Cue Biopharma to Present at the 16th Annual PEGS Boston Essential Protein Engineering & Cell Therapy Summit
8/24/2020
Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today a poster presentation featuring Neo-STAT™,
-
Todos Medical Announces $1.2 Million Contract for COVID-19 PCR Testing Equipment & Supplies with Texas-based Laboratory
8/24/2020
Todos Medical Ltd. (OTCQB: TOMDF) , an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it has entered into a sales agreement with a Texas-based laboratory to supply it with the necessary testing equipment and supplies for
-
CohBar Announces First Subjects Dosed in its Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity
8/24/2020
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the first subjects have been dosed with CB4211 in the Phase 1b stage of its Phase 1a/1b clinical trial for NASH and obesity
-
Mallinckrodt's Hobart, N.Y. Site Recognized With Two Manufacturing Leadership Awards
8/24/2020
Mallinckrodt Pharmaceuticals, a global biopharmaceutical company, announced that its Specialty Generics business has been recognized as a Manufacturing Leadership Award winner for outstanding achievement by the National Association of Manufacturers.
-
Dr. Michael T. Cohen elected President of the Canadian Medical Protective Association (CMPA)
8/24/2020
The Canadian Medical Protective Association is pleased to announce the election of Dr. Michael Cohen as President of the Association.
-
Humanigen Management Changes
8/24/2020
Humanigen, Inc., today announced the appointment of Edward P. Jordan, MBA, to Chief Commercial Officer, a new role that will report to Dr. Cameron Durrant, Chief Executive Officer of Humanigen, effective immediately.